Thrombin is an enzyme found in the blood plasma that causes:
- Clotting by converting fibrinogen to fibrin.
- The aggregation of platelets that lead to platelet plug formation and aids in the initial phase of the clotting cascade.
- Activation of factors V, VIII, and XI that feedback into the generation of more thrombin.
Drug development process is divided into multiple stages. It starts with basic science research for a new drug in the laboratory.
- This step was successfully accomplished at Ayass Bioscience, LLC, where we identified an aptamer-based blood thinner that is a direct thrombin inhibitor with an antidote to neutralize and reverse the drug effect.
- The second stage is pre-clinical research that is performed on animals in order to address basic safety and efficacy questions followed by clinical trials on human subjects.
Ayass Bioscience, LLC Aptamer discovery does not only lower the cost of blood clotting therapy but also introduces a therapeutic drug with its antidote to neutralize the effect of the medication and avoid excessive bleeding.
Both the drug and antidote are aptamer based, making them cheaper to synthesize, with less batch to batch variation and higher stability than antibody based therapies.